Dr. Ely Benaim serves as the Chief Medical Officer and Executive Vice President of Development at SonALAsense, a biotech firm specializing in sonodynamic therapy for treating aggressive brain tumors such as diffuse intrinsic pontine glioma (DIPG) and recurrent glioblastoma (rGBM). Beginning his career in pediatric oncology at St. Jude Children’s Research Hospital, Dr. Benaim moved on to make significant contributions in drug and device development, holding critical roles at renowned companies like Amgen, Sangamo BioSciences, Millennium Pharmaceuticals, and Rexahn Pharmaceuticals. Before joining SonALAsense, he served as the Chief Medical Officer at Novocure, overseeing key clinical trials and setting new benchmarks in neuro oncology.
At SonALAsense, his extensive background in clinical oncology, bench research, and biopharmaceutical development uniquely equips him to navigate the clinical and regulatory landscape. With an in-depth understanding of patient needs and a focus on translating therapies from the lab to clinical trials, he is guiding the execution and building clinical trial pipeline for sonodynamic therapy. Under his guidance, SonALAsense is committed to bringing revolutionary treatment options to market, offering hope to patients and families battling aggressive brain tumors.
